Clostridioides difficile, a spore-forming and anaerobic gram-positive bacterium, causes a wide-spectrum diarrheal disease that can ultimately lead to life-threatening conditions such as toxic megacolon or colonic perforation.
Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment, Itovebi (inavolisib), providing the oral therapy a place with other niched therapies from Astrazeneca plc and Novartis AG. Itovebi is to be combined with Pfizer Inc.’s palbociclib (Ibrance) and Faslodex (fulvestrant, Astrazeneca) for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer.
Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 million up-front payment for rights to YS-2302018, an oral Lp(a) disruptor. It’s an impressive figure for such an early program, but the Cambridge, U.K.-based pharma hailed the small molecule’s potential against a range of indications, both alone and in combination regimens that could include PCSK9 inhibitor AZD-0780.
CSPC Pharmaceutical Group Ltd. has entered into an exclusive license agreement with Astrazeneca plc for the global development, manufacture and commercialization of CSPC’s lipoprotein(a) (Lp[a]) inhibitor, YS-2302018, and any pharmaceutical or biological product subsequently developed that includes the compound.
Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 million up-front payment for rights to YS-2302018, an oral Lp(a) disruptor. It’s an impressive figure for such an early program, but the Cambridge, U.K.-based pharma hailed the small molecule’s potential against a range of indications, both alone and in combination regimens that could include PCSK9 inhibitor AZD-0780.
Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. The companies hope that the gBRCA pre-screening solution will not only transform patients’ lives but bring value to health care systems.
Scientists from the Cardiovascular Research Center at the University of Virginia School of Medicine and Astrazeneca plc have developed a new mouse model of cardiovascular disease associated with genetic variations of cholesterol metabolism. The animal allows in vivo studies of myocardial infarction, plaque rupture and stroke.
Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and calcitonin receptors have been developed for treating obesity. Astrazeneca plc reported results with their AMYR3 agonist AZD-6234.
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
